000132485 001__ 132485
000132485 005__ 20240229105018.0
000132485 0247_ $$2doi$$a10.1093/neuonc/nox141
000132485 0247_ $$2pmid$$apmid:29016845
000132485 0247_ $$2pmc$$apmc:PMC5786244
000132485 0247_ $$2ISSN$$a1522-8517
000132485 0247_ $$2ISSN$$a1523-5866
000132485 0247_ $$2altmetric$$aaltmetric:32070368
000132485 037__ $$aDKFZ-2018-00172
000132485 041__ $$aeng
000132485 082__ $$a610
000132485 1001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b0$$eFirst author$$udkfz
000132485 245__ $$aPediatric low-grade gliomas: next biologically driven steps.
000132485 260__ $$aOxford$$bOxford Univ. Press$$c2018
000132485 3367_ $$2DRIVER$$aarticle
000132485 3367_ $$2DataCite$$aOutput Types/Journal article
000132485 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659955578_8497$$xReview Article
000132485 3367_ $$2BibTeX$$aARTICLE
000132485 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132485 3367_ $$00$$2EndNote$$aJournal Article
000132485 520__ $$aDespite the fact that they are not typically life-threatening, low-grade gliomas (LGGs) remain a significant clinical challenge in pediatric neuro-oncology due to comorbidities associated with these tumors and/or their treatments, and their propensity to multiply recurs. LGGs, in total the most common brain tumors arising in childhood, can often become a chronic problem requiring decades of management. The Second International Consensus Conference on Pediatric Low-Grade Gliomas held in Padua, Italy in 2016 was convened in an attempt to advance the pace of translating biological discoveries on LGGs into meaningful clinical benefit. Topics discussed included: the implications of our growing biological understanding of the genomics underlying these tumors; the assessment of the model systems available; the implications of the molecular and histopathologic differences between adult and pediatric diffuse gliomas; and steps needed to expedite targeted therapy into late-stage clinical trials for newly diagnosed cases. Methods for the diagnostic assessment of alterations in the Ras/mitogen-activated protein kinase pathway, typical for these tumors, were also considered. While the overall tone was positive, with a consensus that progress is being and will continue to be made, the scale of the challenge presented by this complex group of tumors was also acknowledged. The conclusions and recommendations of the meeting panel are provided here as an outline of current thinking and a basis for further discussion.
000132485 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000132485 588__ $$aDataset connected to CrossRef, PubMed,
000132485 7001_ $$aKieran, Mark W$$b1
000132485 7001_ $$aBouffet, Eric$$b2
000132485 7001_ $$aAlexandrescu, Sanda$$b3
000132485 7001_ $$aBandopadhayay, Pratiti$$b4
000132485 7001_ $$aBornhorst, Miriam$$b5
000132485 7001_ $$aEllison, David$$b6
000132485 7001_ $$aFangusaro, Jason$$b7
000132485 7001_ $$aFisher, Michael J$$b8
000132485 7001_ $$aForeman, Nicholas$$b9
000132485 7001_ $$aFouladi, Maryam$$b10
000132485 7001_ $$aHargrave, Darren$$b11
000132485 7001_ $$aHawkins, Cynthia$$b12
000132485 7001_ $$aJabado, Nada$$b13
000132485 7001_ $$aMassimino, Maura$$b14
000132485 7001_ $$aMueller, Sabine$$b15
000132485 7001_ $$aPerilongo, Giorgio$$b16
000132485 7001_ $$aSchouten van Meeteren, Antoinette Y N$$b17
000132485 7001_ $$aTabori, Uri$$b18
000132485 7001_ $$aWarren, Katherine$$b19
000132485 7001_ $$aWaanders, Angela J$$b20
000132485 7001_ $$aWalker, David$$b21
000132485 7001_ $$aWeiss, William$$b22
000132485 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b23$$udkfz
000132485 7001_ $$aWright, Karen$$b24
000132485 7001_ $$aZhu, Yuan$$b25
000132485 7001_ $$aBowers, Daniel C$$b26
000132485 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b27$$udkfz
000132485 7001_ $$aPacker, Roger J$$b28
000132485 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nox141$$gVol. 20, no. 2, p. 160 - 173$$n2$$p160 - 173$$tNeuro-Oncology$$v20$$x1523-5866$$y2018
000132485 909CO $$ooai:inrepo02.dkfz.de:132485$$pVDB
000132485 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132485 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000132485 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000132485 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000132485 9141_ $$y2018
000132485 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000132485 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132485 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000132485 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132485 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132485 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132485 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132485 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132485 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132485 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132485 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000132485 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000132485 980__ $$ajournal
000132485 980__ $$aVDB
000132485 980__ $$aI:(DE-He78)B062-20160331
000132485 980__ $$aUNRESTRICTED